LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Ironwood Pharmaceuticals Inc

Open

SectorGezondheidszorg

1.32 3.94

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.26

Max

1.36

Belangrijke statistieken

By Trading Economics

Inkomsten

61M

24M

Verkoop

44M

85M

K/W

Sectorgemiddelde

92.77

35.724

Winstmarge

27.686

Werknemers

253

EBITDA

76M

47M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-20.63% downside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

85M

206M

Vorige openingsprijs

-2.62

Vorige sluitingsprijs

1.32

Nieuwssentiment

By Acuity

50%

50%

172 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ironwood Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 apr 2025, 14:26 UTC

Belangrijke Marktbewegers

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial

Peer Vergelijking

Prijswijziging

Ironwood Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

-20.63% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 1 USD  -20.63%

Hoogste 1 USD

Laagste 1 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ironwood Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

N/A / 0.9337Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

172 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.